Article detail · 2014
Everolimus for women with trastuzumab resistant HER2 positive advanced breast cancer BOLERO 3 a randomised double blind placebo controlled phase 3 trial
YÖKSİS
OpenAlex
SJR Q1
JCR Q1
Citations 495
Top 1%
Percentile 99.8%
FWCI 32.23
- Year
- 2014
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue The Lancet Oncology
- Catalog match (ISSN) The Lancet Oncology
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
Abstract not compiled yet; it will appear after the DergiPark / OpenAlex queue runs.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
495 citations
OpenAlex cited_by_count (cache / database)
8 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance 2016
- Tyrosine Kinase Inhibitors 2019
- mTOR inhibitors from a diagnostic perspective: radiolabeling of everolimus and its nanoformulation, in vitro incorporation assays against cervix and ovarian cancer cells 2022
- mTOR inhibitors from a diagnostic perspective: radiolabeling of everolimus and its nanoformulation, in vitro incorporation assays against cervix and ovarian cancer cells 2022
- mTOR inhibitors from a diagnostic perspective: radiolabeling of everolimus and its nanoformulation, in vitro incorporation assays against cervix and ovarian cancer cells 2022
- mTOR inhibitors from a diagnostic perspective: radiolabeling of everolimus and its nanoformulation, in vitro incorporation assays against cervix and ovarian cancer cells 2022
- mTOR inhibitors from a diagnostic perspective: radiolabeling of everolimus and its nanoformulation, in vitro incorporation assays against cervix and ovarian cancer cells 2021
- Tyrosine Kinase Inhibitors 2016